Physiological control of liver glycogen metabolism: Lessons from novel glycogen phosphorylase inhibitors

Mini-Reviews in Medicinal Chemistry

Volumn 10, Issue 12, 2010, Pages 1175-1187

  Agius, L ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Glycogen; Glycogen phosphorylase; Hepatocytes; Inhibitors; Liver

Indexed keywords

GLUCOSE; GLUCOSE 6 PHOSPHATE; GLYCOGEN; GLYCOGEN PHOSPHORYLASE; GLYCOGEN SYNTHASE; INDOLE; PHOSPHOPROTEIN PHOSPHATASE 1;

ALLOSTERISM; ARTICLE; BINDING SITE; CATALYSIS; DRUG TARGETING; GLYCOGEN LIVER LEVEL; GLYCOGEN METABOLISM; GLYCOGEN SYNTHESIS; GLYCOGENOLYSIS; HUMAN; LIVER CELL; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN DEPHOSPHORYLATION;

EID: 78549257789     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389557511009011175     Document Type: Article

References (84)

1. Cherrington, A.D. Banting Lecture 1997. Control of glucose uptakeand release by the liver in vivo. Diabetes, 1999, 48,1198-1214.
2. Basu, A.; Shah P.; Nielsen M.; Basu, R.; Rizza, R.A. Effects oftype 2 diabetes on the regulation of hepatic glucose metabolism. JInvestig Med., 2004, 52, 366-374.
3. Basu, A.; Rizza, R.A. Glucose effectiveness: measurement in dia-betic and nondiabetic humans. Exp Clin Endocrinol Diabetes.2001, 109(Suppl 2), S157-165.
4. Hawkins, M.; Gabriely, I.; Wozniak, R.; Reddy, K.; Rossetti, L.; Shamoon, H. Glycemic control determines hepatic and peripheralglucose effectiveness in type 2 diabetic subjects. Diabetes., 2002 51, 2179-2189.
5. Treadway, J.L.; Mendys, P.; Hoover, D.J. Glycogen phosphorylaseinhibitors for the treatment of type 2 diabetes mellitus. Expert OpinInvestig Drugs., 2001, 10, 439-454.
6. Henke, B.R.; Sparks, S.M. Glycogen phosphorylase inhibitors. Mini Rev. Med. Chem., 2006, 6, 845-857.
7. Agius, L. New hepatic targets for glycaemic control in diabetes. Best Pract. Res. Clin. Endocrinol. Metab., 2007, 21, 587-605
8. Bollen, M., Keppens, S.; Stalmans, W. Specific features of glyco-gen metabolism in the liver. Biochem. J., 1998, 336, 19-31.
9. Agius, L. Glucokinase and molecular aspects of liver glycogenmetabolism. Biochem. J., 2008, 414, 1-18.
10. Van Schaftingen, E.; Gerin, I. The glucose-6-phosphatase system.Biochem. J., 2002, 362, 513-532.
11. Newgard, C.B.; Brady, M.J.; O'Doherty, R.M.; Saltiel, A.R. Organ-izing glucose disposal: emerging roles of the glycogen targetingsubunits of protein phosphatase-1. Diabetes, 2000, 49, 1967-1977.
12. Munro, S.; Ceulemans, H.; Bollen, M.; Diplexcito, J.; Cohen. P.T.A novel glycogen-targeting subunit of protein phosphatase 1 that isregulated by insulin and shows differential tissue distribution inhumans and rodents. FEBS J., 2005, 272, 1478-1489.
13. De la Iglesia, N.; Mukhtar, M.; Seoane, I.; Guinovart, J.J.; Agius,L. The role of the regulatory protein of glucokinase in the glucosesensory mechanism of the hepatocyte. J. Biol. Chem., 2000, 275,10597-10603.
14. Ferrer, J.C.; Favre, C.; Gomis, R.R.; Fernández-Novell, J.M.; Gar-cía-Rocha, M.; de la Iglesia, N.; Cid, E.; Guinovart, J.J. Control ofglycogen deposition. FEBS Lett., 2003, 546, 127-132.
15. Aiston, S.; Andersen, B.; Agius, L. Glucose 6-phosphate regulateshepatic glycogenolysis through inactivation of phosphorylase. Dia-betes., 2003, 52, 1333-1339.
16. Aiston, S.; Green, A.; Mukhtar, M.; Agius, L. Glucose 6-phosphatecauses translocation of phosphorylase in hepatocytes and inacti-vates the enzyme synergistically with glucose. Biochem. J., 2004,377, 195-204.
17. Fernández-Novell, J.M.; Roca, A.; Bellido, D.; Vilaró, S.; Guino-vart, J.J. Translocation and aggregation of hepatic glycogen syn-thase during the fasted-to-refed transition in rats. Eur. J. Biochem.,1996, 238, 570-575.
18. Ros, S.; García-Rocha, M.; Domínguez, J.; Ferrer, J.C.; Guinovart, J.J. Control of liver glycogen synthase activity and intracellular dis-tribution by phosphorylation. J. Biol. Chem., 2009, 284, 6370-6378.
19. Carabaza, A.; Ciudad, C.J.; Baqué, S.; Guinovart, J.J. Glucose hasto be phosphorylated to activate glycogen synthase, but not to inac-tivate glycogen phosphorylase in hepatocytes. FEBS Lett., 1992,296, 211-214.
20. Carabaza, A.; Ricart, M.D.; Mor, A.; Guinovart, J.J.; Ciudad, C.J. Role of AMP on the activation of glycogen synthase and phos-phorylase by adenosine, fructose, and glutamine in rat hepatocytes. J. Biol. Chem., 1990, 265, 2724-2732.
21. Ciudad, C.J.; Carabaza, A.; Guinovart, J.J. Glucose 6-phosphateplays a central role in the activation of glycogen synthase by glu-cose in hepatocytes. Biochem Biophys Res Commun., 1986, 141,1195-1200.
22. Doherty, M.J.; Moorhead, G.; Morrice, N.; Cohen, P.; Cohen, P.T. Amino acid sequence and expression of the hepatic glycogen-binding (GL)-subunit of protein phosphatase-1. FEBS Lett., 1995,375, 294-298
23. Browne, G.J.; Delibegovic, M.; Keppens, S.; Stalmans, W.; Cohen, P.T. The level of the glycogen targetting regulatory subunit R5 ofprotein phosphatase 1 is decreased in the livers of insulin-dependent diabetic rats and starved rats. Biochem. J., 2001, 360,449-459.
24. García-Rocha, M.; Roca, A.; De La Iglesia, N.; Baba, O.;Fernández-Novell, J.M.; Ferrer, J.C.; Guinovart, J.J. Intracellulardistribution of glycogen synthase and glycogen in primary culturedrat hepatocytes. Biochem. J., 2001, 357, 17-24.
25. Newgard, C.B.; Hwang, P.K.; Fletterick, R.J. The family of glycogen phosphorylases: structure and function. Crit. Rev. Biochem.Mol. Biol., 1989, 24, 69-99.
26. Johnson, L.N. Glycogen phosphorylase: control by phosphorylationand allosteric effectors. FASEB J., 1992, 6, 2274-2282.
27. Johnson, L.N.; Snape P.; Martin, J.L.; Acharya, K.R.; Barford, D.; Oikonomakos, N.G. Crystallographic binding studies on the allos-teric inhibitor glucose-6-phosphate to T state glycogen phosphorylase b. J. Mol. Biol., 1993, 232, 253-267.
28. Pautsch, A.; Stadler, N.; Wissdorf, O.; Langkopf, E.; Moreth, W.; Streicher, R. Molecular recognition of the protein phosphatase 1glycogen targeting subunit by glycogen phosphorylase. J. Biol.Chem., 2008, 283, 8913-8918.
29. Rath, V.L., Ammirati, M.; Danley, D.E.; Ekstrom, J.L.; Gibbs, E.M.; Hynes, T.R.; Mathiowetz, A.M.; McPherson, R.K.; Olson, T.V.; Treadway, J.L.; Hoover, D.J. Human liver glycogen phosphorylase inhibitors bind at a new allosteric site. Chem. Biol., 2000,9, 677-682.
30. Oikonomakos, N.G.; Skamnaki, V.T.; Tsitsanou, K.E.; Gavalas, N.G.; Johnson, L.N. A new allosteric site in glycogen phosphorylase b as a target for drug interactions. Structure, 2000 8, 575-584.
31. Kasvinsky, P.J.; Shechosky, S.; Fletterick, R.J. Synergistic regulation of phosphorylase a by glucose and caffeine. J. Biol. Chem.,1978, 253, 9102-9106.
32. Ekstrom, J.L.; Pauly, T.A.; Carty, M.D.; Soeller, W.C.; Culp, J.; Danley, D.E.; Hoover, D.J.; Treadway, J.L.; Gibbs, E.M.; Fletterick, R.J.; Day, Y.S.; Myszka, D.G.; Rath, V.L. Structure-activity analysis of the purine binding site of human liver glycogen phos-phorylase. Chem. Biol., 2002, 9, 915-924.
33. Ercan-Fang, N.G.; Nuttall, F.Q.; Gannon, M.C. Uric acid inhibitsliver phosphorylase a activity under simulated in vivo conditions. Am. J. Physiol. Endocrinol. Metab., 2001, 280, E248-253.
34. Shang, J.; Lehrman, M.A. Activation of glycogen phosphorylasewith 5-aminoimidazole-4-carboxamide riboside (AICAR). Assess-ment of glycogen as a precursor of mannosyl residues in glycocon-jugates. J. Biol. Chem., 2004, 279, 12076-80.
35. Ercan-Fang, N.; Taylor, M.R.; Treadway, J.L.; Levy, C.B.; Genereux, P.E.; Gibbs, E.M.; Rath, V.L.; Kwon, Y.; Gannon, M.C.; Nuttall, F.Q. Endogenous effectors of human liver glycogenphosphorylase modulate effects of indole-site inhibitors. Am. J.Physiol. Endocrinol. Metab., 2005, 289, E366-372.
36. Ercan-Fang, N.; Gannon, M.C.; Rath, V.L.; Treadway, J.L.; Taylor, M.R.; Nuttall, F.Q. Integrated effects of multiple modulators onhuman liver glycogen phosphorylasen a. Am. J. Physiol. Endocrinol. Metab., 2002, 283, E29-37.
37. Ercan, N.; Gannon, M.C.; Nuttall, F.Q. Allosteric regulation ofliver phosphorylase a: revisited under approximated physiologicalconditions. Arch. Biochem. Biophys., 1996, 328, 255-264.
38. Aiston, S.; Trinh, K.; Lange, A.J.; Newgard, C.B.; Agius, L. Glu-cose 6-phosphatase overexpression lowers glucose 6-phosphate andinhibits glycogen synthesis and glycolysis without affecting glu-cokinase translocation: evidence against feedback inhibition of glu-cokinase. J. Biol. Chem., 1999, 274, 24559-24566.
39. Hampson, L.J.; Agius, L. Increased potency and efficacy by com-bined phosphorylase inactivation and glucokinase activation in thecontrol of hepatocyte glycogen metabolism. Diabetes, 2005, 54,617-623
40. Cadefau, J.; Bollen, M.; Stalmans, W. Glucose-induced glycogene-sis in the liver involves the glucose-6-phosphate-dependentdephosphorylation of glycogen synthase. Biochem. J., 1997, 322,745-50.
41. Board, M. N-Acetyl-beta-D-glucopyranosylamine 6-phosphate is aspecific inhibitor of glycogen-bound protein phosphatase 1. Bio-chem. J. 1997, 328, 695-700.
42. Clore, J.N.; Stillman, J.; Sugerman, H. Glucose-6-phosphatase fluxin vitro is increased in type 2 diabetes. Diabetes, 2000, 49, 969-974.
43. Caro, J.F.; Triester, S.; Patel, V.K.; Tapscott, E.B.; Frazier, N.L.; Dohm, G.L. Liver glucokinase: decreased activity in patients with type II diabetes. Horm. Metab. Res.,1995, 27, 19-22.
44. Willms, B.; Ben-Ami, P.; Soling, H-D. Hepatic enzyme activities ofglycolysis and gluconeogenesis in diabetes of man and laboratoryanimals. Horm. Metab. Res.1970 2, 135-141.
45. Alemany, S.; Cohen, P. Phosphorylase a is an allosteric inhibitor ofthe glycogen and microsomal forms of rat hepatic protein phospha-tase-1. FEBS Lett. 1986, 198, 194-202.
46. Martin, W.H.; Hoover, D.J.; Armento, S.J.; Stock, I.A.; McPherson, R.K.; Danley, D.E.; Stevenson, R.W.; Barrett, E.J.; Treadway, J.L. Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo. Proc. Natl. Acad. Sci. USA,1998, 95, 1776-1781.
47. Aiston, S.; Hampson, L.; Gomez-Foix, A.M.; Guinovart, J.J.; Agius L. Hepatic glycogen synthesis is highly sensitive to phosphorylaseactivity: Evidence from metabolic control analysis. J. Biol Chem.,2001, 276, 23858-23866.
48. Zibrova, D.; Grempler, R.; Streicher, R.; Kauschke, S.G. Inhibitionof the interaction between protein phosphatase 1 glycogen-targeting subunit and glycogen phosphorylase increases glycogensynthesis in primary rat hepatocytes. Biochem. J., 2008, 412, 359-366.
49. Kelsall, I.R.; Rosenzweig, D.; Cohen, P.T. Disruption of the allos-teric phosphorylase a regulation of the hepatic glycogen-targetedprotein phosphatase 1 improves glucose tolerance in vivo. Cell Sig-nal., 2009, 21,1123-1134.
50. Somsák, L.; Czifrák, K.; Tóth, M.; Bokor, E.; Chrysina, E.D.; Alexacou, K.M.; Hayes J.M.; Tiraidis, C.; Lazoura, E.; Leonidas, D.D.; Zographos, S.E.; Oikonomakos, N.G. New inhibitors of glycogen phosphorylase as potential antidiabetic agents. Curr. Med.Chem., 2008, 15, 2933-2983.
51. Oikonomakos, N.G.; Somsák, L. Advances in glycogen phosphory-lase inhibitor design. Curr. Opin. Investig. Drugs, 2008, 9, 379-395.
52. Martin, J.L.; Veluraja, K.; Ross, K.; Johnson, L.N.; Fleet, G.W.; Ramsden, N.G.; Bruce, I.; Orchard, M.G.; Oikonomakos, N.G.; Papageorgiou, A.C. Glucose analogue inhibitors of glycogen phos-phorylase: the design of potential drugs for diabetes. Biochemistry,1991, 30, 10101-10116.
53. Watson, K.A.; Mitchell, E.P.; Johnson, L.N.; Son, J.C.; Bichard, C.J.; Orchard, M.G.; Fleet, G.W.; Oikonomakos, N.G.; Leonidas, D.D.; Kontou, M. Design of inhibitors of glycogen phosphorylase:a study of alpha- and beta-C-glucosides and 1-thio-beta-D-glucosecompounds. Biochemistry, 1994, 33, 5745-5758.
54. Oikonomakos, N.G.; Kontou, M.; Zographos, S.E.; Watson, K.A.; Johnson, L.N.; Bichard, C.J.; Fleet, G.W.; Acharya, K.R. N-acetyl-beta-D-glucopyranosylamine: a potent T-state inhibitor of glycogenphosphorylase. A comparison with alpha-D-glucose. Protein Sci.,1995, 4, 2469-2477.
55. Gregoriou, M.; Noble, M.E.; Watson KA, Garman EF, Krulle TM, de la Fuente C, Fleet GW, Oikonomakos NG, Johnson LN. Thestructure of a glycogen phosphorylase glucopyranose spirohydantoin complex at 1.8 A resolution and 100 K: the role of the waterstructure and its contribution to binding. Protein Sci., 1998, 7, 915-927.
56. Board, M.; Bollen, M.; Stalmans, W.; Kim, Y.; Fleet, G.W.; Johnson, L.N. Effects of C-1-substituted glucose analogue on the activation states of glycogen synthase and glycogen phosphorylase in rathepatocytes. Biochem. J., 1995, 311, 845-852
57. Board, M.; Hadwen, M.; Johnson, L.N. Effects of novel analoguesof D-glucose on glycogen phosphorylase activities in crude extractsof liver and skeletal muscle. Eur. J. Biochem., 1995, 228,753-761.
58. Andersen, B.; Westergaard, N. The effect of glucose on the potencyof two distinct glycogen phosphorylase inhibitors. Biochem. J.,2002, 367, 443-50.
59. Massillon, D.; Bollen, M.; De Wulf, H.; Overloop, K.; Vanstapel, F.; Van Hecke, P.; Stalmans, W. Demonstration of a glyco-gen/glucose 1-phosphate cycle in hepatocytes from fasted rats. Se-lective inactivation of phosphorylase by 2-deoxy-2-fluoro-alpha-D-glucopyranosyl fluoride. J. Biol. Chem., 1995, 270, 19351-19356
60. Andersen, B.; Rassov, A.; Westergaard, N.; Lundgren, K. Inhibi-tion of glycogenolysis in primary rat hepatocytes by 1, 4-dideoxy-1,4-imino-D-arabinitol. Biochem. J., 1999, 342, 545-550.
61. Fosgerau, K.; Westergaard, N.; Quistorff, B.; Grunnet, N.; Kristi-ansen, M.; Lundgren, K. Kinetic and functional characterization of1,4-dideoxy-1, 4-imino-d-arabinitol: a potent inhibitor of glycogenphosphorylase with anti-hyperglyceamic effect in ob/ob mice. Arch. Biochem. Biophys., 2000, 380, 274-284.
62. Oikonomakos, N.G.; Tiraidis, C.; Leonidas, D.D.; Zographos, S.E.; Kristiansen, M.; Jessen, C.U.; Norskov-Lauritsen, L.; Agius, L. Iminosugars as potential inhibitors of glycogenolysis: structural in-sights into the molecular basis of glycogen phosphorylase inhibition. J. Med. Chem., 2006 49, 5687-5701.
63. Latsis, T.; Andersen, B.; Agius, L. Diverse effects of two allostericinhibitors on the phosphorylation state of glycogen phosphorylasein hepatocytes. Biochem. J., 2002, 368, 309-316.
64. Bergans, N.; Stalmans, W.; Goldmann, S.; Vanstapel, F. Molecularmode of inhibition of glycogenolysis in rat liver by the dihydro-pyridine derivative, BAY R3401: inhibition and inactivation ofglycogen phosphorylase by an activated metabolite. Diabetes,2000, 49, 1419-1426.
65. Zographos, S.E.; Oikonomakos, N.G.; Tsitsanou, K.E.; Leonidas, D.D.; Chrysina, E.D.; Skamnaki, V.T.; Bischoff, H.; Goldmann, S.; Watson, K.A.; Johnson, L.N. The structure of glycogen phosphory-lase b with an alkyldihydropyridine-dicarboxylic acid compound, anovel and potent inhibitor. Structure, 1997, 5,1413-1425.
66. Shiota, M.; Jackson, P.A.; Bischoff, H.; McCaleb, M.; Scott, M.; Monohan, M.; Neal, D.W.; Cherrington, A.D. Inhibition of glyco-genolysis enhances gluconeogenic precursor uptake by the liver ofconscious dogs. Am J Physiol., 1997, 273, E868-879.
67. Wen, X.; Sun, H.; Liu, J.; Cheng, K.; Zhang, P.; Zhang, L.; Hao, J.; Zhang, L.; Ni, P.; Zographos, S.E.; Leonidas, D.D.; Alexacou, K.M.; Gimisis, T.; Hayes, J.M.; Oikonomakos, N.G. Naturally oc-curring pentacyclic triterpenes as inhibitors of glycogen phosphory-lase: synthesis, structure-activity relationships, and X-ray crystallo-graphic studies. J. Med. Chem., 2008, 51, 3540-3554.
68. Klabunde, T.; Wendt, K.U.; Kadereit, D.; Brachvogel, V.; Burger, H.J.; Herling, A.W.; Oikonomakos, N.G.; Kosmopoulou, M.N.; Schmoll, D.; Sarubbi, E.; von Roedern, E.; Schönafinger, K.; De-fossa, E. Acyl ureas as human liver glycogen phosphorylase inhibi-tors for the treatment of type 2 diabetes. J. Med. Chem., 2005, 48,6178-93.
69. Oikonomakos, N.G.; Kosmopoulou, M.N.; Chrysina, E.D.; Leoni-das, D.D.; Kostas, I.D.; Wendt, K.U.; Klabunde, T.; Defossa, E.Crystallographic studies on acyl ureas, a new class of glycogenphosphorylase inhibitors, as potential antidiabetic drugs. ProteinSci., 2005, 14, 1760-1771.
70. Anderka, O.; Loenze, P.; Klabunde, T.; Dreyer, M.K.; Defossa, E.; Wendt, K.U.; Schmoll, D. Thermodynamic characterization of al-losteric glycogen phosphorylase inhibitors. Biochemistry, 2008, 47,4683-4691.
71. Kristiansen, M.; Andersen, B.; Iversen, L.F.; Westergaard, N. Identification, synthesis, and characterization of new glycogen phos-phorylase inhibitors binding to the allosteric AMP site. J. Med.Chem., 2004, 47, 3537-3545.
72. Oikonomakos, N.G.; Zographos, S.E.; Skamnaki, V.T.; Archontis, G. The 1.76 A resolution crystal structure of glycogen phosphory-lase B complexed with glucose, and CP320626, a potential antidia-betic drug. Bioorg. Med. Chem., 2002, 10, 1313-1319.
73. Oikonomakos, N.G.; Chrysina, E.D.; Kosmopoulou, M.N.; Leonidas, D.D. Crystal structure of rabbit muscle glycogen phosphory-lase a in complex with a potential hypoglycaemic drug at 2.0 Aresolution. Biochim. Biophys. Acta, 2003, 1647, 325-332.
74. L.; Greenberg, C.C.; Brady, M.J.; Freeman, S.; Poucher, S.M.; Agius, L. Increased sensitivity of glycogen synthesis to phosphorylase-a and impaired expression of the glycogen targeting protein R6 inhepatocytes from insulin resistant Zucker fa/fa rats. FEBS J., 2006,273, 1989-1999.
75. Gustafson, L.A.; Neeft, M.; Reijngoud, D.J.; Kuipers, F.; Sauer-wein, H.P.; Romijn, J.A.; Herling, A.W.; Burger, H.J.; Meijer, A.J. Fatty acid and amino acid modulation of glucose cycling in isolatedrat hepatocytes. Biochem. J., 2001, 358, 665-671.
76. Kelsall, I.R.; Munro, S.; Hallyburton, I.; Treadway, J.L.; Cohen, P.T. The hepatic PP1 glycogen-targeting subunit interaction withphosphorylase a can be blocked by C-terminal tyrosine deletion oran indole drug. FEBS Lett., 2007, 581, 4749-4753.
77. Kaiser, A.; Nishi, K.; Gorin, F.A.; Walsh, D.A.; Bradbury, E.M.; Schnier, J.B. The cyclin-dependent kinase (CDK) inhibitor flavopiridol inhibits glycogen phosphorylase. Arch. Biochem. Bio-phys., 2001, 386, 179-187.
78. Oikonomakos, N.G.; Schnier, J.B.; Zographos, S.E.; Skamnaki, V.T.; Tsitsanou, K.E.; Johnson, L.N. Flavopiridol inhibits glycogenphosphorylase by binding at the inhibitor site. J. Biol. Chem., 2000,275, 34566-34573.
79. Hampson, L.J.; Arden, C.; Agius, L.; Ganotidis, M.; Kosmopoulou, M.N.; Tiraidis, C.; Elemes, Y.; Sakarellos, C.; Leonidas, D.D.; Oikonomakos, N.G. Bioactivity of glycogen phosphorylase inhibi-tors that bind to the purine nucleoside site. Bioorg. Med. Chem.,2006, 14, 7835-7845.
80. Cohen, P.T. Protein phosphatase 1--targeted in many directions. J.Cell Sci., 2002, 115, 241-256.
81. Cohen, P. The twentieth century struggle to decipher insulin signal-ling. Nat. Rev. Mol. Cell Biol., 2006 7, 867-873.
82. Aiston, S.; Coghlan, M.P.; Agius, L. Inactivation of phosphorylaseis a major component of the mechanism by which insulin stimu-lates hepatic glycogen synthesis. Eur. J. Biochem., 2003, 270,2773-2781.
83. Fosgerau, K.; Breinholt, J.; McCormack, J.G.; Westergaard, N. Evidence against glycogen cycling of gluconeogenic substrates invarious liver preparations. J. Biol. Chem., 2002, 277, 28648-28655
84. Hampson, L.J.; Mackin, P.; Agius, L. Stimulation of glycogensynthesis and inactivation of phosphorylase in hepatocytes by sero-tonergic mechanisms, and counter-regulation by atypical antipsy-chotic drugs. Diabetologia, 2007, 50, 1743-1751.